Repositioning Candidates
Repositioning candidates for NAFLD are derived from DrugBank which fall into three categories: therapeutic strategy-associated, target-associated, and indication-associated candidates. For each candidate, detailed properties are extracted from DrugBank, and related strategies, target and NAFLD-associated disease in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
1608 records.
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R1001 | DB06399 | investigational | biotech | Atacicept | Indication associated | Details |
| R1002 | DB06401 | approved; investigational | small molecule | Bazedoxifene | Indication associated | Details |
| R1003 | DB06402 | approved | small molecule | Telavancin | Indication associated | Details |
| R1004 | DB06403 | approved; investigational | small molecule | Ambrisentan | Indication associated | Details |
| R1005 | DB06405 | investigational | small molecule | Eprodisate | Therapeutic strategy associated | Details |
| R1006 | DB06406 | investigational | small molecule | Idraparinux | Indication associated | Details |
| R1007 | DB06413 | approved; investigational | small molecule | Armodafinil | Indication associated | Details |
| R1008 | DB06421 | investigational | small molecule | Declopramide | Therapeutic strategy associated | Details |
| R1009 | DB06423 | investigational | biotech | Endostatin | Therapeutic strategy associated | Details |
| R1010 | DB06429 | investigational | small molecule | Talnetant | Indication associated | Details |
| R1011 | DB06431 | investigational | small molecule | Evernimicin | Indication associated | Details |
| R1012 | DB06433 | investigational | small molecule | Tezacitabine | Therapeutic strategy associated | Details |
| R1013 | DB06435 | investigational | small molecule | Tarazepide | Indication associated | Details |
| R1014 | DB06437 | investigational | small molecule | Tifacogin | Indication associated | Details |
| R1015 | DB06441 | approved | small molecule | Cangrelor | Therapeutic strategy associated | Details |
| R1016 | DB06444 | investigational | small molecule | Dexanabinol | Target associated | Details |
| R1017 | DB06447 | investigational | small molecule | E5531 | Target associated | Details |
| R1018 | DB06448 | approved; investigational | small molecule | Lonafarnib | Therapeutic strategy associated | Details |
| R1019 | DB06449 | investigational | small molecule | Ilodecakin | Indication associated | Details |
| R1020 | DB06455 | investigational | small molecule | Meclinertant | Indication associated | Details |
| R1021 | DB06464 | investigational | biotech | IR501 | Indication associated | Details |
| R1022 | DB06467 | investigational | biotech | Apolizumab | Therapeutic strategy associated | Details |
| R1023 | DB06469 | investigational | small molecule | Lestaurtinib | Therapeutic strategy associated | Details |
| R1024 | DB06470 | investigational | small molecule | Clomethiazole | Indication associated | Details |
| R1025 | DB06472 | investigational | small molecule | Fradafiban | Therapeutic strategy associated | Details |
| R1026 | DB06479 | investigational | small molecule | Propentofylline | Therapeutic strategy associated | Details |
| R1027 | DB06480 | approved | small molecule | Prucalopride | Indication associated | Details |
| R1028 | DB06486 | investigational | small molecule | Enzastaurin | Therapeutic strategy associated | Details |
| R1029 | DB06492 | investigational | biotech | Mirococept | Indication associated | Details |
| R1030 | DB06495 | investigational | biotech | Onercept | Therapeutic strategy associated | Details |
| R1031 | DB06497 | investigational | small molecule | Aplaviroc | Target associated | Details |
| R1032 | DB06503 | investigational | biotech | MLN2222 | Therapeutic strategy associated | Details |
| R1033 | DB06506 | investigational | small molecule | Repinotan | Indication associated | Details |
| R1034 | DB06510 | investigational | small molecule | Muraglitazar | Target associated | Details |
| R1035 | DB06511 | investigational | biotech | AMGN-0007 | Target associated | Details |
| R1036 | DB06518 | investigational | small molecule | R-1487 | Indication associated | Details |
| R1037 | DB06519 | investigational | small molecule | Edaglitazone | Indication associated | Details |
| R1038 | DB06521 | investigational | small molecule | Ertiprotafib | Target associated | Details |
| R1039 | DB06527 | investigational | small molecule | Tramiprosate | Indication associated | Details |
| R1040 | DB06532 | investigational | small molecule | Pafuramidine | Indication associated | Details |
| R1041 | DB06533 | investigational | small molecule | Ragaglitazar | Target associated | Details |
| R1042 | DB06536 | investigational | small molecule | Tesaglitazar | Target associated | Details |
| R1043 | DB06538 | investigational | small molecule | Robalzotan | Indication associated | Details |
| R1044 | DB06546 | investigational | biotech | Atibuclimab | Therapeutic strategy associated | Details |
| R1045 | DB06548 | investigational | small molecule | Minodronic acid | Indication associated | Details |
| R1046 | DB06569 | investigational | small molecule | P-57AS3 | Indication associated | Details |
| R1047 | DB06576 | investigational | biotech | Baminercept | Indication associated | Details |
| R1048 | DB06582 | investigational | small molecule | Dextofisopam | Indication associated | Details |
| R1049 | DB06586 | investigational | small molecule | Cetilistat | Therapeutic strategy associated | Details |
| R1050 | DB06587 | investigational | small molecule | Mitemcinal | Indication associated | Details |
| R1051 | DB06589 | approved | small molecule | Pazopanib | Therapeutic strategy associated | Details |
| R1052 | DB06595 | approved; investigational | small molecule | Midostaurin | Therapeutic strategy associated | Details |
| R1053 | DB06599 | investigational | biotech | Lexatumumab | Therapeutic strategy associated | Details |
| R1054 | DB06600 | investigational | small molecule | Nemonoxacin | Indication associated | Details |
| R1055 | DB06602 | approved; investigational | biotech | Reslizumab | Therapeutic strategy associated | Details |
| R1056 | DB06604 | investigational | small molecule | Ilepatril | Indication associated | Details |
| R1057 | DB06605 | approved | small molecule | Apixaban | Indication associated | Details |
| R1058 | DB06606 | investigational | biotech | Teplizumab | Indication associated | Details |
| R1059 | DB06607 | approved; investigational; withdrawn | biotech | Catumaxomab | Therapeutic strategy associated | Details |
| R1060 | DB06609 | investigational | small molecule | Odiparcil | Indication associated | Details |
| R1061 | DB06610 | investigational | small molecule | Omiganan | Indication associated | Details |
| R1062 | DB06611 | investigational | biotech | Pegsunercept | Indication associated | Details |
| R1063 | DB06612 | approved; investigational | biotech | Mepolizumab | Therapeutic strategy associated | Details |
| R1064 | DB06618 | investigational | small molecule | Cutamesine | Indication associated | Details |
| R1065 | DB06624 | investigational | small molecule | Taranabant | Indication associated | Details |
| R1066 | DB06630 | investigational | small molecule | Anacetrapib | Indication associated | Details |
| R1067 | DB06641 | investigational | small molecule | Perifosine | Therapeutic strategy associated | Details |
| R1068 | DB06642 | investigational | biotech | Bevasiranib | Indication associated | Details |
| R1069 | DB06643 | approved | biotech | Denosumab | Target associated | Details |
| R1070 | DB06651 | investigational | small molecule | DiaPep 277 | Indication associated | Details |
| R1071 | DB06652 | investigational | small molecule | Vicriviroc | Target associated | Details |
| R1072 | DB06656 | investigational | small molecule | TAS-106 | Therapeutic strategy associated | Details |
| R1073 | DB06660 | investigational | small molecule | Saredutant | Indication associated | Details |
| R1074 | DB06669 | investigational | small molecule | Arverapamil | Indication associated | Details |
| R1075 | DB06670 | investigational | small molecule | Odanacatib | Indication associated | Details |
| R1076 | DB06674 | approved | biotech | Golimumab | Therapeutic strategy associated | Details |
| R1077 | DB06677 | investigational | small molecule | Clazosentan | Indication associated | Details |
| R1078 | DB06679 | investigational | biotech | Amediplase | Indication associated | Details |
| R1079 | DB06682 | investigational | small molecule | Naproxcinod | Indication associated | Details |
| R1080 | DB06689 | approved | small molecule | Ethanolamine oleate | Therapeutic strategy associated | Details |
| R1081 | DB06692 | approved; investigational; withdrawn | biotech | Aprotinin | Therapeutic strategy associated | Details |
| R1082 | DB06693 | experimental | small molecule | Mevastatin | Target associated | Details |
| R1083 | DB06696 | experimental; investigational | small molecule | Arbekacin | Indication associated | Details |
| R1084 | DB06703 | approved | small molecule | Gadobutrol | Indication associated | Details |
| R1085 | DB06709 | approved; investigational | small molecule | Methacholine | Therapeutic strategy associated | Details |
| R1086 | DB06712 | approved; investigational | small molecule | Nilvadipine | Indication associated | Details |
| R1087 | DB06725 | approved; investigational | small molecule | Lornoxicam | Therapeutic strategy associated | Details |
| R1088 | DB06729 | approved | small molecule | Sulfaphenazole | Indication associated | Details |
| R1089 | DB06736 | approved; investigational | small molecule | Aceclofenac | Therapeutic strategy associated | Details |
| R1090 | DB06742 | approved; investigational | small molecule | Ambroxol | Therapeutic strategy associated | Details |
| R1091 | DB06755 | approved; nutraceutical | small molecule | Beta carotene | Therapeutic strategy associated | Details |
| R1092 | DB06757 | approved; nutraceutical | small molecule | Manganese | Target associated | Details |
| R1093 | DB06771 | approved | small molecule | Besifloxacin | Indication associated | Details |
| R1094 | DB06772 | approved | small molecule | Cabazitaxel | Therapeutic strategy associated | Details |
| R1095 | DB06777 | approved | small molecule | Chenodeoxycholic acid | Target associated | Details |
| R1096 | DB06778 | approved | small molecule | Cupric sulfate | Therapeutic strategy associated | Details |
| R1097 | DB06779 | approved | small molecule | Dalteparin | Indication associated | Details |
| R1098 | DB06781 | approved | small molecule | Difluprednate | Therapeutic strategy associated | Details |
| R1099 | DB06784 | approved | small molecule | Gallium citrate Ga-67 | Therapeutic strategy associated | Details |
| R1100 | DB06786 | approved; investigational; withdrawn | small molecule | Halcinonide | Therapeutic strategy associated | Details |